Thursday, September 28, 2006. Day-At-A-Glance

iseh06.book Page 7 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

7

THURSDAY, SEPTEMBER 28, 2006 DAY-AT-A-GLANCE 07:00–08:00

Meet the Professor

16:45–18:15 Exhibits, Job Fair, and Poster Session I Exhibit Hall p.8 Cedar Lake Lake Nokomis

Micki Bhatia David Scadden 08:00–09:30

Plenary Session 2

Nicollet A-C

09:30–10:00

Break

10:00–11:15

Concurrent Sessions 1

1-1. 1-2. 1-3. 1-4.

AML Mesenchymal Stem Cells (MSC) NK Cells Hematopoietic Stem Cells 1

11:15–12:15

p.8 Exhibit Hall

16:45–18:15 Poster Session I AML - Clinical and Basic Cellular Therapies DNA Damage and Repair Erythropoiesis - Normal and Disease Genetic Manipulation and Gene Therapy Genomics and Gene Expression GVH/GVLD Hematopoietic Stem Cells Immune Reconstitution Immunotherapy Marrow Failure Stem Cell Biology 1

18:15–20:15 Emerging Leaders Task Force Session Lake Calhoun

Nicollet A-C

Developing a Scientific Career in a Changing Landscape - A Panel Discussion by Industry and Academia p.19

Guy Sauvageau

p.10 20:15

Break / Exhibits

12:15–13:15

Lunch Symposium

Exhibit Hall

Greenway ABIJ

Intellectual Property and Marketing Issues related to Cells and Cell-based Therapeutics (Lunch will be available for registered attendees) 13:30–15:00

Plenary Session 3

Stem Cell Homing / Engagement of the Niche / Signal Crosstalk 15:00–15:30

Break

15:30–16:45

Concurrent Sessions 2

p.13 13 14 14 14 15 15 15 17 18 18 18

Nicollet D1 p.8 Nicollet D2 8 Nicollet D3 9 Mirage 9

McCulloch & Till Lecture

12:15–13:30

Exhibit Hall

p.10

Nicollet A-C p.10 Exhibit Hall

2-1. GVL/GVHD/ Immune Reconstitution Nicollet D1 p.11 2-2. Transduction, Hematopoietic Growth Factors, Receptors and Signal Nicollet D2 11 2-3. Oncogenes, Tumor Suppressor Genes Nicollet D3 11 2-4. Niche 1 Mirage 12 2-5. Genetic Manipulation and Gene Therapy Lake Superior A 12

Emerging Leaders Task Force Reception Greenway AJ p.19

Thursday

Gene Therapy

p. 13

iseh06.book Page 8 Thursday, August 17, 2006 4:11 PM

8

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

07:00–08:00

Cedar Lake Lake Nokomis

MEET THE PROFESSOR with Micki Bhatia (McMaster University, Hamilton, Canada) David Scadden (Massachusetts General Hospital, Boston, MA, USA) Aimed at young investigators, but open to all meeting attendees, Meet the Professor breakfast sessions are designed to provide an opportunity to interact with established experts in an intimate setting. Each session is limited to 15 people to allow for greater interaction and quality discussion.

08:00–09:30

Nicollet A-C

PLENARY SESSION 2 GENE THERAPY Chair: Hans Peter Kiem (Seattle, WA, USA) 8

9

Mutagenesis by Retroviral Vector Insertion Manifestation and Prevention Christopher Baum (Hannover Medical School, Hannover Germany & Cincinnati Children's Hospital, Cincinnati, OH, USA) Safety and Efficacy of Hematopoietic Stem Cell Gene Transfer in Large Animal Models Hans Peter Kiem (Fred Hutchison Cancer Research Center, Seattle, WA, USA)

10

Gene Therapy of X-linked Chronic Granulomatous Disease Manuel Grez (Georg-Speyer-Haus, Frankfurt, Germany)

11

High-efficiency Human Genome Editing using Designed Zinc Finger Nucleases Fyodor Urnov (Sangamo Biosciences, Richmond, CA, USA)

10:00–11:15

CONCURRENT SESSIONS 1 These abstracts are also presented as posters. The poster session (Thursday or Friday) and poster board number are given in parentheses after the abstract number.

10:00–11:15

Nicollet D1

Concurrent Session 1-1 AML Chair: Dominique Bonnet (London, UK) 12 (T9) MULTIDRUG RESISTANCE EFFECTED BY BCL-2 IN AML IS TRANSCRIPTIONALLY REGULATED DOWNSTREAM FROM FLT3 THROUGH A JNK PATHWAY TO C-JUN/ATF2: A NOVEL JNK INHIBITOR CAUSES APOPTOSIS IN PATIENT BLASTS A. Wilson-Weekes1*, L. D. Cripe1, A. D. Hartmans1, G. Friedman3, P. Worland3, B. Bennett3, L. M. Boxer2, M. J. Klemsz5, H. Nakshatri5, H. S. Boswell1,4,5 1 Division of Hematology, Indiana University, IN, USA; 2Division of Hematology, Stanford University, Stanford, CA, USA; 3Celgene Corporation, Summit, NJ, USA; 4VAMC, Indianapolis, IN, USA; 5Walther Oncology Center, Indianapolis, IN, USA 13 (T8) THE SPECIFIC AURORA KINASE INHIBITOR AZD1152 SIGNIFICANTLY AFFECTS THE GROWTH OF HUMAN LEUKAEMIC CELLS IN AN IN VIVO AML MODEL D. Pearce1*, R. Odedra2, R. Wilkinson2, D. Bonnet1 1 Cancer Research UK, London Research Institute, UK; 2AstraZeneca, Alderley Park, UK 14 (T7) CD44-LIGATION TRIGGERS IL-1, GM-CSF AND IL-8 DRIVEN DIFFERENTIATION PATHWAYS IN HUMAN MONOBLASTIC LEUKEMIA CELLS J. Delaunay, J. Qi, Z. Gadhoum, L. Durand, C. Chomienne, F. Smadja-Joffe* Inserm U718 Saint-Louis Hospital, Paris, France 15 (T6) A NOVEL AND RAPID IN VIVO SYSTEM FOR STUDYING HUMAN HEMATOPOIETIC MALIGNANCIES V. R. Deutsch2*, M. Taizi1, A. Ohana1, R. S. Goldstein1 1 Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel 52900; 2The Hematology Institute, Tel Aviv Sourasky Medical Center, Weizmann St. 6, Tel Aviv, Israel

10:00–11:15

Nicollet D2

Concurrent Session 1-2 Mesenchymal Stem Cells (MSC) Chair: Graça Almeida-Porada (Reno, NV, USA)

09:30–10:00

Exhibit Hall

Break

16 (T19) MESENCHYMAL STROMAL CELLS, GROWN AS HIGHDENSITY 3D CULTURE, PROMOTE ENGRAFTMENT OF HUMAN UMBILICAL CORD BLOOD (hUCB) DERIVED CD34+ CELLS IN NOD-SCID MICE O. Burger1*, L. Michael1, M. Rusanovsky1, N. Bercovich1, Y. Rozen1, O. Marom1, L. Frolov1, G. Rosenblat1, S. Meretzki1, A. J. Treves2, A. Kadouri3, J. M. Rowe4,5, A. Nagler2 1 Pluristem Life Systems Inc, Haifa, Israel; 2Sheba Medical Center, Tel Hashomer, Israel; 3Rainbow Biotechnologies, Luzern, Switzerland; 4Rappoport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel; 5Rambam Medical Center, Haifa, Israel

iseh06.book Page 9 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34 17 (T17) MESENCHYMAL STEM CELLS HAVE VASCULOTROPIC AND VASCULOPROTECTIVE FUNCTIONS THAT ARE BENEFICIAL IN ISCHEMIA/REPERFUSION INJURY OF THE KIDNEY F. Tögel1,2*, C. Lange3, A. R. Zander3, C. Westenfelder1,2 1University of Utah, Medicine/Nephrology, Salt Lake City, UT, USA; 2University of Utah, Physiology, Salt Lake City, UT, USA; 3University of Hamburg, Bone Marrow Transplantation, Hamburg, Germany

19 (F29) MESENCHYMAL STEM CELLS RESCUE HEMATOPOIESIS IN LETHALLY IRRADIATED MICE C. Lange1*, A. Spiess2, A. R. Zander1 1Dept. Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 2Dept. Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany 20 (F66) ALTERATIONS IN HOST IMMUNITY FOLLOWING IN UTERO TRANSPLANTATION OF HUMAN MESENCHYMAL STEM CELLS (MSC) T. Yamagami*, C. Porada, J. Chamberlain, E. Zanjani, G. AlmeidaPorada Department of Animal Biotechnology, University of Nevada, Reno, Reno, NV, USA

10:00–11:15

Nicollet D3

Concurrent Session 1-3 NK Cells Chair: Dan Kaufman (Minneapolis, MN, USA) 21 (T18) ENHANCED CORD BLOOD (CB) NATURAL KILLER (NK) SUBSETS AND NK RECEPTOR EXPRESSION AFTER EXVIVO EXPANSION (EVE): POSSIBLE USE FOR ADOPTIVE CELLULAR IMMUNOTHERAPY (ACI) J. Ayello1*, P. Satwani1, N. Day1, R. J. Wapner2, C. van de Ven1, E. Shereck1, W. Lomerzow1, M. S. Cairo1,3,4 1Department of Pediatrics, NewYork-Presbyterian, Columbia University, New York, NY, USA; 2Department of Obstetrics & Gynecology, NewYork-Presbyterian, Columbia University, New York, NY, USA; 3Department of Pathology, NewYork-Presbyterian, Columbia University, New York, NY, USA; 4Department of Medicine, NewYork-Presbyterian, Columbia University, New York, NY, USA 22 (T15) CYTOLYTIC ACTIVITIES OF INHIBITORY NK CELL RECEPTOR (CD94/NKG2A)-EXPRESSING CD8 T CELLS EXPANDED BY DIFFERENT CYTOKINES J. Tanaka1*, J. Sugita1, N. Kato1, T. Toubai1, J. Ibata1, Y. Shono1, S. Ota2, M. Asaka2, M. Imamura1 1Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 2Third Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

23 (T71) SIGNIFICANT DIFFERENCES IN NATURAL KILLER (NK) CELL SUBSETS AND NATURAL KILLER RECEPTOR (NKR) EXPRESSION IN PERIPHERAL BLOOD (PB) VERSUS CORD BLOOD (CB): IMPLICATIONS IN IMMATURITY OF CB (NEONATAL) INNATE IMMUNITY E. Shereck1*, P. Satwani1, C. van de Ven1, R. J. Wapner2, N. Day1, H. Jiang1, M. S. Cairo1,3,4 1Departments of Pediatrics; 2Obstetrics/Gynecology; 3Pathology; 4and Medicine, Morgan Stanley Children's Hospital of NewYorkPresbyterian, Columbia University, New York, NY, USA 24 (T72) A SUBPOPULATION OF HUMAN NK CELLS LACKING INHIBITORY RECEPTORS FOR SELF MHC IS DEVELOPMENTALLY IMMATURE RATHER THAN AUTOREACTIVE S. Cooley1*, F. Xiao1, M. Pitt1, M. Gleason1, V. McCullar1, T. Bergemann2, K. McQueen3, L. Guethlein3, P. Parham3, J. S. Miller1 1 Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, USA; 2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA; 3Department of Structural Biology, Sherman Fairchild Building, 299 Campus Drive West, Stanford University School of Medicine, Stanford, CA, USA 25 (F49) DISTINCT DIFFERENCES IN NK CELL COMPARED TO T CELL DEVELOPMENT FROM HUMAN EMBRYONIC STEM CELLS P. S. Woll*, C. H. Martin, D. S. Kaufman Stem Cell Institute and Dept. of Medicine, University of Minnesota, Minneapolis, MN, USA

10:00–11:15

Mirage

Concurrent Session 1-4 Hematopoietic Stem Cells 1 Chair: Guy Sauvageau (Montreal, Canada) 26 (T66) COMPLEMENTARY AND INDEPENDENT FUNCTION FOR HOXB4 AND BMI1 IN HSC SELF-RENEWAL A. Faubert1,2*, G. Sauvageau1,2,3 1Laboratory of Molecular Genetics of Hematopoietic Stem Cells, Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, Quebec, Canada; 2Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada; 3Department of Medicine and Division of Haematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada 27 (T63) A CRITICAL ROLE FOR SMAD4 IN THE SELF-RENEWAL OF HEMATOPOIETIC STEM CELLS G. Karlsson1*, U. Blank1, J. L. Moody1, M. Ehinger2, S. Singbrant1, C. X. Deng3, S. Karlsson1 1Molecular Medicine and Gene Therapy and Lund Stem Cell Center, Lund University Hospital, Sweden; 2Department of Pathology, Helsingborgs Lasarett, Sweden; 3National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA 28 (T64) OPPOSING CRITICAL ROLES OF THROMBOPOIETIN AND LNK IN REGULATING HEMATOPOIETIC STEM CELL EXPANSION J. Antonchuk*, N. Buza-Vidas, J. M. Nygren, R. Månsson, C. T. Jensen, H. Qian, S. E. W. Jacobsen Stem Cell Center, University of Lund, Lund, Sweden

Thursday

18 (T14) SUCCESSFUL TREATMENT OF ACCIDENTAL RADIATION BURNS BY LOCAL ADMINISTRATION OF AUTOLOGOUS MESENCHYMAL STEM CELLS J-J. Lataillade1*, C. Doucet1, H. Carsin2, E. Bey3, A. Chapel4, M. Benderiter4, J-F. Bottolier-Depois4, D. Thierry4, T. De Revel5, P. Gourmelon4 1 Centre de Transfusion Sanguine des Armées, Unité de Thérapie Cellulaire, BP410, 92141 Clamart, France; 2Hôpital des Armées Percy, Centre de Traitement des Brûlés, BP406, 92141 Clamart, France; 3Hôpital des Armées Percy, Service de Chirurgie Plastique, BP406, 92141 Clamart, France; 4Institut de Radioprotection et de Sureté Nucléaire IRSN/DRPH, BP17, 92262 Fontenay aux Roses, France; 5Hôpital des Armées Percy, Service d'Hématologie, BP406, 92141 Clamart, France

9

iseh06.book Page 10 Thursday, August 17, 2006 4:11 PM

10

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

29 (T60) A LIMITED ROLE FOR P21 IN MAINTAINING NORMAL HEMATOPOIETIC STEM CELL FUNCTIONING R. van Os*, L. M. Kamminga, A. Ausema, L. Bystrykh, D. Draijer, B. Dontje, G. de Haan Department of Cell Biology, section Stem Cell Biology, University Medical Center Groningen, Groningen, The Netherlands 30 (T57) SMAD5 IS DISPENSABLE FOR ADULT MURINE HEMATOPOIESIS S. Singbrant1*, J. L. Moody1, U. Blank1, G. Karlsson1, L. Umans2, A. Zwijsen2, S. Karlsson1 1 Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University Hospital, Lund, Sweden; 2Department of Developmental Biology, Flanders Interuniversity Institute for Biotechnology (VIB) and Laboratory of Molecular Biology (Celegen), University of Leuven, Leuven, Belgium

11:15–12:15

Nicollet A-C

13:30–15:00

PLENARY SESSION 3 STEM CELL HOMING / ENGAGEMENT OF THE NICHE / SIGNAL CROSSTALK Chair: Paul Simmons (East Melbourne, Australia) Most Hematopoietic Stem Cells appear to Reside in Vascular Niches within the Bone Marrow and Extramedullary Tissues Sean Morrison (Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA)

32

33

Hemopoietic Stem Cells Within Their Niche Susie Nilsson (Australian Stem Cell Centre, Melbourne, Australia)

34

Quiescent Stem Cells and Osteoblastic Niche Toshio Suda (Keio University, School of Medicine, Department of Cell Differentiation, Tokyo, Japan)

McCULLOCH & TILL LECTURE Chair: Stefan Karlsson (Lund, Sweden) 31

Regulation of HSC Self-Renewal by Hox and Polycomb Group Genes Guy Sauvageau (IRIC Université de Montreal, Montreal, Canada)

Hot Topic Presentation 35

12:15–13:30

Exhibit Hall

Break / Exhibits

12:15–13:15

Nicollet A-C

THE INTEGRINS OF α4β1 AND α9β1 MEDIATE INTERACTION WITH AND REGULATION OF HEMOPOIETIC STEM CELLS BY OSTEOPONTIN D. N. Haylock1*, H. M. Johnston2, G. A. Whittty1, R. J. Webb2, S. K. Nilsson1 1Hemopoietic Stem Cell Niche Laboratory, Australian Stem Cell Centre, Melbourne, Australia; 2Peter MacCallum Cancer Centre, Melbourne, Australia

Greenway ABIJ

LUNCH SYMPOSIUM INTELLECTUAL PROPERTY AND MARKETING ISSUES RELATED TO CELLS AND CELL-BASED THERAPEUTICS Dr. Moore (Director, University of Minnesota, Patents/Technology Marketing) Dr. Ellinger (Managing Principal, Fish & Richardson P.C.) Mr. Haider (CEO, BioE Pharmaceutical Company) Mr. William (B.J.) Lehmann (President and COO, Athersys, Inc.) The panel will discuss intellectual property and marketing issues related to cells and cell-based therapeutics, with particular focus on stem cells. Topics will include patent claim strategies and recent developments in the patent case law that shed light on how much information is required in a patent application to support cell-related claims. A University of Minnesota representative will discuss University perspectives on protecting and licensing cell-based inventions, and the CEO of a biotech company will discuss his experiences in protecting and marketing clonal lines of nonembryonic, multipotential stem cells.

(Lunch will be available for registered attendees)

15:00–15:30

Exhibit Hall

Break

iseh06.book Page 11 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

15:30–16:45

15:30–16:45

CONCURRENT SESSIONS 2 These abstracts are also presented as posters. The poster session (Thursday or Friday) and poster board number are given in parentheses after the abstract number.

15:30–16:45

Nicollet D1

Concurrent Session 2-1 GVL/GVHD / Immune Reconstitution

36 (T36) IN-VIVO DEPLETION OF HUMAN ACTIVATED DENDRITIC CELLS PREVENTS GRAFT VERSUS HOST DISEASE IN A HUMAN-MOUSE CHIMERIC MODEL J. Wilson1*, H. Cullup1,2, A. Rice1, D. N. J. Hart1, D. Munster1 1Mater Medical Research Instutute, South Brisbane, Australia; 2 Haematological Sciences, University of Newcastle Upon Tyne, UK 37 (T35) INCREASED EXPRESSION OF CD86 AND CXCR4 IN CD14+ CELLS IN PERIPHERAL BLOOD AND BONE MARROW OF PATIENTS WITH CHRONIC GVHD M. Arpinati1*, G. Chirumbolo1, M. Baccarani1, D. Rondelli1,2 1 Institute of Hematology 'Seragnoli', University of Bologna, Italy; 2 Hematology/Oncology Section, University of Illinois at Chicago, Chicago, IL, USA 38 (T34) INDUCTION OF POTENT GRAFT-VS-MALIGNANCY EFFECTS USING MISMATCHED DONOR LYMPHOCYTES WHILE AVOIDING GRAFT-VS-HOST DISEASE S. Slavin1*, R. Or1, A. Ackerstein1, S. Samuel1, M. Y. Shapira1, I. Resnick1, M. Bitan1, M. Aker2, Y. Gelfand1, S. Morecki1 1Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel; 2Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel 39 (T68) DIFFERENTIAL GENE EXPRESSION AND PROTEIN PRODUCTION DURING MATURATION PROCESS OF CORD BLOOD (CB) VERSUS ADULT PERIPHERAL BLOOD (APB) MONOCYTE (MO) INTO MATURE DENDRITIC CELLS (DC): INSIGHT INTO IMMATURITY OF CB CELLULAR IMMUNITY H. Jiang1*, C. Wade-Harris1, M. Lim5, L. Baxi2, M. S. Cairo1,3,4 1Departments of Pediatrics; 2Obstetrics & Gynecology; 3Pathology; 4 and Medicine, NewYork-Presbyterian, Columbia University, New York, NY, USA; 5Department of Pathology, University of Utah, Salt Lake City, UT, USA 40 (T78) LYMPHOCYTES EXPANSION, V-BETA SHIFTING, AND REGULATORY T CELL SUPPRESSION IN IMMUNEMEDIATED BONE MARROW FAILURE J. Chen*, N. S. Young Hematology Branch, National Heart Lung and Blood Institute, National Institute of Health, Bethesda, MD, USA

Nicollet D2

Concurrent Session 2-2 Transduction, Hematopoietic Growth Factors, Receptors and Signal Chair: Tucker LeBien (Minneapolis, MN, USA) 41 (F82) DIFFERENTIAL IL-7 SIGNALING PATHWAY ACTIVATION IN NORMAL HUMAN T AND B-LINEAGE PROGENITORS N. Shah1*, S. E. Johnson1, T. W. LeBien1,2 1 The Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Dept. of Laboratory Medicine and Pathology 42 (F81) INVESTIGATING THE ROLE OF RAS HOMOLOGUE ENRICHED IN BRAIN LIKE-1 (RHEBL1) IN MURINE HEMATOPOIESIS T. B. Campbell1,2*, W. Tao1,2, H. E. Broxmeyer1,2 1 Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN, USA; 2Walther Oncology Center, Walther Cancer Institute, Indianapolis, IN, USA 43 (F80) THE ROLE OF CXCL12 IN ACUTE LYMPHOBLASTIC LEUKEMIA IN VIVO: POTENTIAL THERAPEUTIC ROLE FOR CXCR4 ANTAGONISTS L. J. Bendall1,2*, J. Juarez1,2, A. Dela Pena1,2, R. Baraz1,2, J. Hewson1, A. Cisterne1,2, K. F. Bradstock3 1 Westmead Millennium Institute, Westmead, Sydney, NSW, Australia; 2University of Sydney, Westmead, Sydney, NSW, Australia; 3Westmead Hospital, Westmead, Sydney, NSW, Australia 44 (F79) AN INTACT TRANSFORMING GROWTH FACTOR-BETA (TGFβ) SIGNAL TRANSDUCTION PATHWAY IS REQUIRED FOR MIGRATION AND PROLIFERATION OF BONE MARROW STROMAL CELLS TO THE IRRADIATED LUNG J. S. Greenberger*, Y. Niu, X. Zhang, D. Franicola, M. W. Epperly Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA 45 (F77) TIMING OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR ADMINISTRATION BASED ON BONE MARROW CELL KINETICS FOLLOWING CHEMOTHERAPY IN MICE M. Y. Yankelevich1*, M. A. Goodell2, J. Kaplan3 1 Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA; 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; 3Department of Pediatrics, Wayne State University, Detroit, MI, USA

15:30–16:45

Nicollet D3

Concurrent Session 2-3 Oncogenes, Tumor Suppressor Genes Chair: Vittorio Rizzoli (Parma, Italy) 46 (T62) HEDGEHOG/MEIS1 COLLABORATION GENERATES A MIXED-LINEAGE B-LYMPHOID/MYELOID MURINE LEUKEMIA K. Detmer1*, B. Argiropoulos2, A. N. Walker3, A. J. Lowrey1, R. K. Humphries2 1 Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, GA, USA; 2Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada; 3Department of Pathology, Mercer University School of Medicine, Macon, GA, USA

Thursday

Chair: Jerome Ritz (Boston, MA, USA)

11

iseh06.book Page 12 Thursday, August 17, 2006 4:11 PM

12

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

47 (F41) IDENTIFICATION OF MN1 AS A CANDIDATE ONCOGENE IN HEMATOPOIESIS M. Heuser1*, B. Argiropoulos1, J. Krauter2, A. Schambach3, Nv Neuhoff4, C. Baum3, B. Schlegelberger4, A. Ganser2, R. K. Humphries1 1Terry Fox Laboratory, British Columbia Cancer Agency, Canada; 2 Hematology, Hemostasis and Oncology, Hannover Medical School, Germany; 3Experimental Hematology, Hannover Medical School, Germany; 4Cellular and Molecular Pathology, Hannover Medical School, Germany

53 (T59) EXPERIMENTAL EVIDENCE THAT POOR MOBILIZATION IN IMMUNODEFICIENT SCID PATIENTS COULD BE EXPLAINED BY THE LACK OF COMPLEMENT ACTIVATION AND COMPLEMENT-DEPENDENT TRIGGERING OF HSPC RELEASE FROM THE BONE MARROW R. G. Reca1*, M. Wysoczynski1, M. Kucia1, A. JanowskaWieczorek2, J. Ratajczak1, M. Z. Ratajczak1 1Stem Cell Biology Progam at the James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA; 2Department of Medicine, University of Alberta and CBS Edmonton, AB Canada

48 (F39) OVEREXPRESSION OF LYL1 GENE INDUCES T- AND BCELL LEUKEMIA IN MICE Y. Zhong1*, L. Jiang1, S. Toyokuni1, H. Hiai2, Y. Yamada1 1 Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Japan; 2Shiga Medical Center for Adults, Moriyama, Shiga, Japan

101 (T80) CULTIVATION OF HUMAN EMBRYONIC STEM CELLDERIVED EMBRYOID BODIES UNDER DEFINED ENVIRONMENTAL CONDITIONS C. M. Cameron1*, F. Harding1,2, W-S. Hu1, D. S. Kaufman2 1Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN, USA; 2Stem Cell Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

49 (F40) MLL-ELL AND FLT3 ITD COLLABORATE IN TRANSFORMATION OF A MURINE MAST CELL LINE INVOLVING DOWNSTREAM TARGETS C-JUN, P53, AND GATA1 E. M. Chan1,2*, A. Wilson-Weekes2, A. D. Hartman2, L. M. Pelus1, S. Fukuda1, M. J. Thirman4, H. S. Boswell1,2,3 1 Walther Oncology Center, Indianapolis, IN, USA; 2Division of Hematology, Indiana University Medical Center, Indianapolis, IN, USA; 3VA Medical Center, Indianapolis, IN, USA; 4University of Chicago Hospitals, Chicago, IL, USA

15:30–16:45

Mirage

Concurrent Session 2-4 Niche 1 Chair: Susie Nilsson (Melbourne, Australia) 50 (T65) SPATIO-TEMPORAL EMERGENCE OF MULTIPOTENT HEMATOPOIETIC PRECURSORS IN THE ZEBRAFISH EMBRYO J. Y. Bertrand*, A. D. Kim, D. Traver Department of Cell and Developmental Biology, University of California San Diego, San Diego, CA, USA 51 (T61) CIRCULATION PLAYS AN ESSENTIAL ROLE IN DISTRIBUTING HEMATOPOIETIC PROGENITORS FROM THE YOLK SAC TO THE EMBRYO PROPER; LESSONS FROM THE NCX1-NULL MOUSE C. Lux1*, M. Yoshimoto1, K. McGrath2, S. Conway1, J. Palis2, M. C. Yoder1 1 Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA; 2Department of Pediatrics, Center for Pediatric Biomedical Research, University of Rochester School of Medicine, Rochester, NY, USA 52 (T58) RAC1 IS REQUIRED FOR HEMATOPOIETIC STEM/ PROGENITOR CELL SEEDING OF FETAL LIVER G. Ghiaur1,3*, M. J. Ferkovicz2, J. R. Bailey1, J. A. Cancelas1,4, M. C. Yoder2, D. A. Williams1,3 1 Experimental Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; 2Indiana University School of Medicine, Indianapolis, MN, USA; 3Molecular and Developmental Biology Graduate Program, University of Cincinnati, Cincinnati, OH, USA; 4Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH, USA

15:30–16:45

Lake Superior A

Concurrent Session 2-5 Genetic Manipulation and Gene Therapy Chair: Christopher Baum (Hannover, Germany) 54 (T29) A THERAPEUTIC MODEL FOR TYPE 1 GAUCHER DISEASE I. Berglin Enquist1*, E. Nilsson1, A. Ooka1, J. E. Mansson2, K. Olsson1, M. Ehinger3, J. Richter1, S. Karlsson1 1 Molecular Medicine and Gene Therapy, Lund University, Lund, Sweden; 2Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Molndal, Sweden; 3Department of Pathology, Lund University Hospital, Lund, Sweden 55 (T28) CORRECTION OF SEVERE COMBINED IMMUNE DEFICIENCY IN MULTIPOTENT ADULT PROGENITOR CELLS BY SPLICEOSOME-MEDIATED RNA TRANSSPLICING AND SLEEPING BEAUTY TRANSPOSON DELIVERY H. Zayed1, L. Xia1, A. Yerich1, S. R. Yant3, M. A. Kay3, M. Puttaraju4, G. Mansfield4, D. L. Wiest5, R. S. McIvor2, J. Tolar1*, B. R. Blazar1 1 University of Minnesota Cancer Center, Department of Pediatrics, Division of Hematology-Oncology, Blood and Marrow Transplantation, Minneapolis, MN, USA; 2Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA; 3Department of Pediatrics, Stanford University School of Medicine, Stanford. CA, USA; 4Intronn, Inc., Gaithersburg, MD, USA; 5Fox Chase Cancer Center, Division of Basic Sciences, Immunobiology Working Group, Philadelphia, PA 56 (T27) LENTIVIRAL TRANSDUCTION OF MURINE TYR22 DIHYDROFOLATE REDUCTASE PROTECTS AGAINST METHOTREXATE TOXICITY IN MOUSE MARROW TRANSPLANT RECIPIENTS J. L. Gori*, K. Podetz-Pedersen, D. Swanson, A. D. Karlin, N. J. Somia, R. S. McIvor Institute of Human Genetics and Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA 57 (T26) DEVELOPMENT OF A NOVEL COMPETITIVE REPOPULATION ASSAY IN SUBMYELOABLATED HOSTS TO EVALUATE ENGRAFTMENT POTENTIAL A. L. Sinn, J. L. Meyers, B. K. Wyss, K. E. Pollok, W. S. Goebel* Dept. of Pediatrics (Hematology/Oncology) and Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA

iseh06.book Page 13 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34 58 (T25) INTRAVENOUS INJECTION OF MANGANESE SUPEROXIDE DISMUTASE-PLASMID/LIPOSOME (MNSODPL) COMPLEX PROTECTS MICE FROM WHOLE BODY IRRADIATION (WBI) M. W. Epperly*, Y. Niu, J. S. Greenberger Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

16:45–18:15

Exhibit Hall

EXHIBITS, JOB FAIR, and POSTER SESSION I

Exhibit Hall

POSTER SESSION I The poster board number is shown in parentheses, followed by the abstract number.

AML - Clinical and Basic (T1) 126 IS BONE MARROW DAMAGE AND HEMATOPOIETIC TOXICITY A REQUIREMENT FOR CHEMICALLY-INDUCED AML? D. W. Pyatt1,2,3*, C. J. Borgert4,5 1Summit Toxicology, L.L.P., Lafayette, CO, USA; 2University of Colorado MTEHS Program, Denver CO, USA; 3University of Colorado, Biometrics and Preventative Medicine, Denver CO, USA; 4 Applied Pharmacology and Toxicology, Inc., Gainsville, FL, USA; 5 University of Florida, Gainsville, FL, USA (T2) 127 CAN INHALED FORMALDEHYDE RESULT IN HEMATOPOIETIC MALIGNANCIES? D. W. Pyatt1,2*, B. Golden3 1 Summit Toxicology L.L.P., Layafette, CO, USA; 2University of Colorado, Health Sciences Center, Denver CO, USA; 3ToxLogic, Inc., Potomac, MD, USA (T3) 128 NOVEL ANTI-LEUKEMIC AGENTS DERIVED FROM NAPHTHO QUINONES; MODE OF ACTION M. Hallak1*, S. Bittner2, Y. Granot3, I. Nathan1 1Department of Clinical Biochemistry, Ben-Gurion University of the Negev, Beer Sheva, Israel; 2Department of Chemistry, Ben-Gurion University of the Negev, Beer Sheva, Israel; 3Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel (T4) 129 THE CELL MEMBRANE AS A TARGET FOR CANCER DRUG DEVELOPMENT: LEUKAEMIA CELL SURVIVAL AND GROWTH DEPENDS ON PLASMA MEMBRANE ELECTRON TRANSPORT (PMET) P. M. Herst, A. S. Tan, M. V. Berridge* Malaghan Institute of Medical Research, Wellington, New Zealand (T5) 130 ABCIXIMAB (REOPRO), AN ANTITHROMBOTIC AGENT, EFFECTIVELY REDIRECTS THE CYTOLYTIC ACTIVITY OF ACTIVATED T CELLS (ATC) TO TARGET ACUTE MYELOGENOUS LEUKEMIA (AML) VIA BISPECIFIC ANTIBODY (BIAB) TECHNOLOGY P. A. Davol1*, J. M. Gall2, S. D. Olson3, R. Rathore1, L. G. Lum1,2 1 Department of Medicine, Roger Williams Medical Center, Providence, RI, USA; 2Boston University Medical School, Boston, MA, USA; 3North Carolina State University, Raleigh, NC, USA

(T6) 15 A NOVEL AND RAPID IN VIVO SYSTEM FOR STUDYING HUMAN HEMATOPOIETIC MALIGNANCIES V. R. Deutsch2*, M. Taizi1, A. Ohana1, R. S. Goldstein1 1Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel 52900; 2The Hematology Institute, Tel Aviv Sourasky Medical Center, Weizmann St. 6, Tel Aviv, Israel (T7) 14 CD44-LIGATION TRIGGERS IL-1, GM-CSF AND IL-8 DRIVEN DIFFERENTIATION PATHWAYS IN HUMAN MONOBLASTIC LEUKEMIA CELLS J. Delaunay, J. Qi, Z. Gadhoum, L. Durand, C. Chomienne, F. Smadja-Joffe* Inserm U718 Saint-Louis Hospital, Paris, France (T8) 13 THE SPECIFIC AURORA KINASE INHIBITOR AZD1152 SIGNIFICANTLY AFFECTS THE GROWTH OF HUMAN LEUKAEMIC CELLS IN AN IN VIVO AML MODEL D. Pearce1*, R. Odedra2, R. Wilkinson2, D. Bonnet1 1 Cancer Research UK, London Research Institute, UK; 2 AstraZeneca, Alderley Park, UK (T9) 12 MULTIDRUG RESISTANCE EFFECTED BY BCL-2 IN AML IS TRANSCRIPTIONALLY REGULATED DOWNSTREAM FROM FLT3 THROUGH A JNK PATHWAY TO C-JUN/ATF2: A NOVEL JNK INHIBITOR CAUSES APOPTOSIS IN PATIENT BLASTS A. Wilson-Weekes1*, L. D. Cripe1, A. D. Hartmans1, G. Friedman3, P. Worland3, B. Bennett3, L. M. Boxer2, M. J. Klemsz5, H. Nakshatri5, H. S. Boswell1,4,5 1Division of Hematology, Indiana University, IN, USA; 2Division of Hematology, Stanford University, Stanford, CA, USA; 3Celgene Corporation, Summit, NJ, USA; 4VAMC, Indianapolis, IN, USA; 5 Walther Oncology Center, Indianapolis, IN, USA

Cellular Therapies (T10) 131 HYPERTHERMIA INDUCES DIFFERENTIATION AND APOPTOSIS IN K562 ERYTHROLEUKEMIC CELL LINE IN DIFFERENT RANGE OF TEMPERATURE (MILD OR SEVERE TREATMENT CONDITIONS) B. Goliaei1*, L. SharifKhatibi1, A. Kariminia2, N. Heidari1, S. Khoei3 1Laboratory of Biophysics and Molecular Biology, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; 2 Pasteur Institute of Iran, Tehran, Iran; 3Department of Biology, Faculty of Basic Medical Science, Iran University of Medical Science, Tehran, Iran (T11) 132 INCIDENCE OF FETAL-MATERNAL MICROCHIMERISM IN PAROUS CANCER PATIENTS G. L. Gilmore*, M. Holm, Y. Anikanova, B. Haq, S. Lashmi-Jasthy, J. Lister, R. K. Shadduck Western Pennsylvania Cancer Institute, West Penn Hospital, Pittsburgh, PA, USA (T12) 133 NEUROPILIN -1 RECEPTOR BLOCKING ANTIBODIES INDUCE CELL DEATH IN PRIMARY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) B CELLS G. S. Nowakowski*, Y. K. Lee, N. Bone, N. E. Kay Mayo Clinic, Rochester, MN, USA (T13) 134 NOSCAPINE INDUCES APOPTOSIS THROUGH ACTIVATION OF CASPASES AND MITOCHONDRIAL EVENT IN P53-NULL MYELOBLASTIC LEUKEMIA K562 B. Goliaei1*, N. Heidari1, P. Rahimi Moghadam2, M. Mahmoudian2 1Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; 2Razi Institute for Drug Research (RIDR), Department of Pharmacology, Iran University of Medical Sciences (IUMS), Tehran, Iran

Thursday

16:45–18:15

13

iseh06.book Page 14 Thursday, August 17, 2006 4:11 PM

14

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

(T14) 18 SUCCESSFUL TREATMENT OF ACCIDENTAL RADIATION BURNS BY LOCAL ADMINISTRATION OF AUTOLOGOUS MESENCHYMAL STEM CELLS J-J. Lataillade1*, C. Doucet1, H. Carsin2, E. Bey3, A. Chapel4, M. Benderiter4, J-F. Bottolier-Depois4, D. Thierry4, T. De Revel5, P. Gourmelon4 1 Centre de Transfusion Sanguine des Armées, Unité de Thérapie Cellulaire, BP410, 92141 Clamart, France; 2Hôpital des Armées Percy, Centre de Traitement des Brûlés, BP406, 92141 Clamart, France; 3Hôpital des Armées Percy, Service de Chirurgie Plastique, BP406, 92141 Clamart, France; 4Institut de Radioprotection et de Sureté Nucléaire IRSN/DRPH, BP17, 92262 Fontenay aux Roses, France; 5Hôpital des Armées Percy, Service d'Hématologie, BP406, 92141 Clamart, France (T15) 22 CYTOLYTIC ACTIVITIES OF INHIBITORY NK CELL RECEPTOR (CD94/NKG2A)-EXPRESSING CD8 T CELLS EXPANDED BY DIFFERENT CYTOKINES J. Tanaka1*, J. Sugita1, N. Kato1, T. Toubai1, J. Ibata1, Y. Shono1, S. Ota2, M. Asaka2, M. Imamura1 1 Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 2Third Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (T16) 76 BIOVAXID VACCINE THERAPY OF FOLLICULAR LYMPHOMA IN FIRST REMISSION: LONG-TERM FOLLOWUP OF A PHASE II TRIAL AND STATUS OF A CONTROLLED, RANDOMIZED PHASE III TRIAL B. L. Gause1*, C. M. Cohen2, L. M. Katz2, T. M. Watson1, S. Arikian2, A. M. Stergiou2 1 National Cancer Institute, Bethesda, MD, USA; 2Biovest International, Worcester, MA, USA (T17) 17 MESENCHYMAL STEM CELLS HAVE VASCULOTROPIC AND VASCULOPROTECTIVE FUNCTIONS THAT ARE BENEFICIAL IN ISCHEMIA/REPERFUSION INJURY OF THE KIDNEY F. Tögel1,2*, C. Lange3, A. R. Zander3, C. Westenfelder1,2 1 University of Utah, Medicine/Nephrology, Salt Lake City, UT, USA; 2University of Utah, Physiology, Salt Lake City, UT, USA; 3University of Hamburg, Bone Marrow Transplantation, Hamburg, Germany (T18) 21 ENHANCED CORD BLOOD (CB) NATURAL KILLER (NK) SUBSETS AND NK RECEPTOR EXPRESSION AFTER EXVIVO EXPANSION (EVE): POSSIBLE USE FOR ADOPTIVE CELLULAR IMMUNOTHERAPY (ACI) J. Ayello1*, P. Satwani1, N. Day1, R. J. Wapner2, C. van de Ven1, E. Shereck1, W. Lomerzow1, M. S. Cairo1,3,4 1 Department of Pediatrics, NewYork-Presbyterian, Columbia University, New York, NY, USA; 2Department of Obstetrics & Gynecology, NewYork-Presbyterian, Columbia University, New York, NY, USA; 3Department of Pathology, NewYork-Presbyterian, Columbia University, New York, NY, USA; 4Department of Medicine, NewYork-Presbyterian, Columbia University, New York, NY, USA (T19) 16 MESENCHYMAL STROMAL CELLS, GROWN AS HIGHDENSITY 3D CULTURE, PROMOTE ENGRAFTMENT OF HUMAN UMBILICAL CORD BLOOD (hUCB) DERIVED CD34+ CELLS IN NOD-SCID MICE O. Burger1*, L. Michael1, M. Rusanovsky1, N. Bercovich1, Y. Rozen1, O. Marom1, L. Frolov1, G. Rosenblat1, S. Meretzki1, A. J. Treves2, A. Kadouri3, J. M. Rowe4,5, A. Nagler2 1 Pluristem Life Systems Inc, Haifa, Israel; 2Sheba Medical Center, Tel Hashomer, Israel; 3Rainbow Biotechnologies, Luzern, Switzerland; 4Rappoport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel; 5Rambam Medical Center, Haifa, Israel

DNA Damage and Repair (T20) 135 HEMATOPOIETIC STEM AND PROGENITOR CELLS FAIL TO ACTIVATE A G1 CHECKPOINT IN RESPONSE TO DNA DAMAGE M. A. Ryan1*, D. Daria1, E. Tichy2, P. Stambrook2, H. Geiger1 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; 2University of Cincinnati, Cincinnati, OH, USA

Erythropoiesis - Normal and Disease (T21) 136 EFFECT OF NICOTINE ON ERYTHROID CELL DIFFERENTIATION FROM EMBRYONIC STEM CELL IN CULTURE I. B. Gubrij1,2*, K. B. Udupa1,2 1 University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Central Arkansas Veterans Healthcare System, Little Rock, AR, USA (T22) 137 ENHANCING THE SENSITIVITY OF ZINC PROTOPORPHYRIN/HEME RATIOS BY CONCENTRATING RETICULOCYTES P. J. Kling1*, M. E. Chen1, S. E. Blohowiak1, M. K. Georgieff2 1 University of Wisconsin, Madison, WI, USA; 2University of Minnesota, Minneapolis, MN, USA (T23) 138 TNFα AND ITS RECEPTORS ARE DIFFERENTIALLY EXPRESSED DURING IN-VITRO ERYTHROPOIESIS I. Dorn*, P. Lazar, J. Luhm, P. Koritke, S. Malchow, H. Kirchner, P. Schlenke Institute of Immunology and Transfusion Medicine, University of Luebeck, Luebeck, Germany (T24) 139 THROMBOSPONDINS 1 AND 4, TWO ERYTHROPOIETINDEPENDENT PROTEINS PRODUCED BY ENDOTHELIAL CELLS, HAVE DIFFERENT EFFECTS ON EARLY ERYTHROID CELL PRECURSORS G. Sadvakassova*, L. F. Congote Endocrine Laboratory, McGill University Health Centre, Montreal, Canada

Genetic Manipulation and Gene Therapy (T25) 58 INTRAVENOUS INJECTION OF MANGANESE SUPEROXIDE DISMUTASE-PLASMID/LIPOSOME (MNSODPL) COMPLEX PROTECTS MICE FROM WHOLE BODY IRRADIATION (WBI) M. W. Epperly*, Y. Niu, J. S. Greenberger Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA (T26) 57 DEVELOPMENT OF A NOVEL COMPETITIVE REPOPULATION ASSAY IN SUBMYELOABLATED HOSTS TO EVALUATE ENGRAFTMENT POTENTIAL A. L. Sinn, J. L. Meyers, B. K. Wyss, K. E. Pollok, W. S. Goebel* Dept. of Pediatrics (Hematology/Oncology) and Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA (T27) 56 LENTIVIRAL TRANSDUCTION OF MURINE TYR22 DIHYDROFOLATE REDUCTASE PROTECTS AGAINST METHOTREXATE TOXICITY IN MOUSE MARROW TRANSPLANT RECIPIENTS J. L. Gori*, K. Podetz-Pedersen, D. Swanson, A. D. Karlin, N. J. Somia, R. S. McIvor Institute of Human Genetics and Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA

iseh06.book Page 15 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

(T29) 54 A THERAPEUTIC MODEL FOR TYPE 1 GAUCHER DISEASE I. Berglin Enquist1*, E. Nilsson1, A. Ooka1, J. E. Mansson2, K. Olsson1, M. Ehinger3, J. Richter1, S. Karlsson1 1 Molecular Medicine and Gene Therapy, Lund University, Lund, Sweden; 2Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Molndal, Sweden; 3Department of Pathology, Lund University Hospital, Lund, Sweden

Genomics and Gene Expression (T30) 140 DIFFERENTIAL GENE EXPRESSION OF CORD BLOODDERIVED CD34+ AND CD133+ CELLS H. Hemmoranta1*, S. Hautaniemi2, J. Niemi3,4, D. Nicorici3, J. Laine1, O. Yli-Harja3, J. Partanen1, T. Jaatinen1 1 Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland; 2Computational Systems Biology Laboratory, Helsinki University, Helsinki, Finland; 3Institute of Signal Processing, Tampere University of Technology, Tampere, Finland; 4 Institute of Mathematics, Tampere University of Technology, Tampere, Finland (T31) 141 EXAMINATION OF GENE EXPRESSION DATA USING DIMENSIONAL REDUCTION METHODOLOGY: A COMPARATIVE STUDY BETWEEN PRINCIPAL COMPONENT ANALYSIS AND PROJECTION PURSUIT J. Albanese1*, S. K. Schreyer2, J. Fostel3, N. Dainiak4 1 Yale New Haven Center for Emergency Preparedness and Disaster Response, New Haven, CT, USA; 2Chemical Computing Group, Montreal, Canada; 3National Institutes of Health, Bethesda, MD, USA; 4Bridgeport Hospital and Yale University School of Medicine, Bridgeport, CT and New Haven, CT, USA (T32) 142 CHARACTERIZATION OF HEPARANASE GENE SNPS IN HEALTH AND DISEASE O. Ostrovsky1*, M. Korostishevsky2, I. Levite1, M. Leiba1, H. Galski1, I. Vlodavsky3, A. Nagler1 1 Division of Hematology, Chaim Seba Medical Center, Tel Hashomer, Israel; 2Dept. of Human Genetics, Tel Aviv University, Tel Aviv, Israel; 3Cancer and Vascular Biology Research Center, Technion, Haifa, Israel (T33) 143 ARRAY CGH ANALYSIS OF RECURRENT CHROMOSOMAL ABERRATIONS OBSERVED IN RADIATION-INDUCED MICE ACUTE MYELOID LEUKEMIA T. Hirouchi1*, T. Takabatake1, K. Yoshida2, Y. Nitta3, S. Tanaka1, K. Ichinohe1, M. Nakamura4, Y. Oghiso1, K. Tanaka1 1 Cell. Mol. Biol., Group. Dept. Radiobiol., Institute for Environmental Sciences, Japan; 2Radiat. Hazards Research Group, NIRS, Japan; 3Int. Radiat. Inform. Center, RIRBM, Hiroshima Univ., Japan; 4Tohoku Environmental Sciences Co.Ltd, Japan

GVH/GVLD (T34) 38 INDUCTION OF POTENT GRAFT-VS-MALIGNANCY EFFECTS USING MISMATCHED DONOR LYMPHOCYTES WHILE AVOIDING GRAFT-VS-HOST DISEASE S. Slavin1*, R. Or1, A. Ackerstein1, S. Samuel1, M. Y. Shapira1, I. Resnick1, M. Bitan1, M. Aker2, Y. Gelfand1, S. Morecki1 1 Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel; 2Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel (T35) 37 INCREASED EXPRESSION OF CD86 AND CXCR4 IN CD14+ CELLS IN PERIPHERAL BLOOD AND BONE MARROW OF PATIENTS WITH CHRONIC GVHD M. Arpinati1*, G. Chirumbolo1, M. Baccarani1, D. Rondelli1,2 1 Institute of Hematology 'Seragnoli', University of Bologna, Italy; 2 Hematology/Oncology Section, University of Illinois at Chicago, Chicago, IL, USA (T36) 36 IN-VIVO DEPLETION OF HUMAN ACTIVATED DENDRITIC CELLS PREVENTS GRAFT VERSUS HOST DISEASE IN A HUMAN-MOUSE CHIMERIC MODEL J. Wilson1*, H. Cullup1,2, A. Rice1, D. N. J. Hart1, D. Munster1 1 Mater Medical Research Instutute, South Brisbane, Australia; 2Haematological Sciences, University of Newcastle Upon Tyne, UK

Hematopoietic Stem Cells (T37) 144 HYPOXIA EXPANDS PRIMITIVE HEMATOPOIETIC PROGENITOR CELLS FROM MOUSE BONE MARROW DURING IN VITRO CULTURE AND PRESERVES THE COLONY-FORMING ABILITY P. Hummerdal, R. Karlsson, J-I. Jönsson* Dept of Biomedicine and Surgery, Division of Cell Biology, Linköping University, Sweden (T38) 145 TOTAL SAPONINS OF PANAX GINSENG PROMOTE HUMAN CD34+ HEMATOPOIETIC STEM CELL PROLIFERATION AND DIFFERENTIATION J. W. Wang1, S. L. Wang2, R. Jiang1, D. Chen2, Y. P. Wang1*, Y. Wang1,3 1 Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing University of Medical sciences, Chongqing, China; 2Department of Physiology, Chongqing University of Medical Sciences, Chongqing, China; 3Medical University of South Carolina, Charleston, SC, USA (T39) 146 WHO ARE THE PLAYERS IN THE NEIGHBORHOOD: SIGNALING PATHWAYS IN THE HEMATOPOIETIC STEM CELL NICHE H. Paz1*, H. Shafizadeh2, M. Lynch2, U. Ganapati2, J. C. Gasson2,3 1 Molecular Biology IDP, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA, USA; 3Department of Biological Chemistry, UCLA School of Medicine, Los Angeles, CA, USA (T40) 147 BLOOD PROGENITOR CELL ENRICHMENT FROM CLINICAL LEUKAPHERESIS PRODUCT BY MAGNETIC IMMUNOLABELING AND MAGNETOPHORESIS Y. Jing1,2*, L. Moore1, P. S. Williams1, J. J. Chalmers2, B. Bolwell3, M. Zborowski1 1 Department of Biomeidcal Engineering, Cleveland Clinic, Cleveland, OH, USA; 2Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA; 3 Taussing Cancer Center, Cleveland Clinic, Cleveland, OH, USA

Thursday

(T28) 55 CORRECTION OF SEVERE COMBINED IMMUNE DEFICIENCY IN MULTIPOTENT ADULT PROGENITOR CELLS BY SPLICEOSOME-MEDIATED RNA TRANSSPLICING AND SLEEPING BEAUTY TRANSPOSON DELIVERY H. Zayed1, L. Xia1, A. Yerich1, S. R. Yant3, M. A. Kay3, M. Puttaraju4, G. Mansfield4, D. L. Wiest5, R. S. McIvor2, J. Tolar1*, B. R. Blazar 1 University of Minnesota Cancer Center, Department of Pediatrics, Division of Hematology-Oncology, Blood and Marrow Transplantation, Minneapolis, MN, USA; 2Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA; 3Department of Pediatrics, Stanford University School of Medicine, Stanford. CA, USA; 4Intronn, Inc., Gaithersburg, MD, USA; 5Fox Chase Cancer Center, Division of Basic Sciences, Immunobiology Working Group, Philadelphia, PA

15

iseh06.book Page 16 Thursday, August 17, 2006 4:11 PM

16

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

(T41) 148 IN VITRO PROLIFERATION AND EXPANSION OF HEMATOPOIETIC PROGENITORS FROM CHRONIC MYELOID LEUKEMIA PATIENTS BEFORE AND AFTER TREATMENT WITH IMATINIB A. Chávez-González1*, M. Ayala-Sánchez2, E. Sánchez-Valle1, E. Ruíz-Sánchez3, R. Arana-Trejo3, J. Vela-Ojeda2, H. Mayani1 1 Hematopoiesis ad Stem Cel Laboratory, Oncology Research Unit, National Medical Center, IMSS. Mexico City, Mexico; 2Department of Hematology, La Raza Medical Ceter, IMSS. Mexico City, Mexico; 3Genetics Department, Mexico City General Hospital, Mexico City, Mexico (T42) 149 BONE MARROW ASSEMBLY DURING MICE ONTOGENY M. Pelajo-Machado*, J. P. Ayres-Silva, E. Balassiano, L. F. G. Caputo, H. L. Lenzi Department of Pathology, Instituto Oswaldo Cruz/ Fiocruz, Rio de Janeiro/RJ, Brazil (T43) 150 A DYNAMIN 3-ENCODING TRANSCRIPT IS DIFFERENTIALLY EXPRESSED DURING HUMAN MEGAKARYOCYTE DEVELOPMENT W. J. Wang1,2*, A. Hughes1, K. Tsubata1, B. Sundell1, M. H. Shim1, D. Gilligan1,2, J. A. Reems1,2 1 Puget Sound Blood Center & Program, Seattle, WA, USA; 2 Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA (T44) 151 AGM DERIVED STROMAL CELL LINE SECRETES FACTORS THAT ARE CAPABLE OF MAINTAINING HSC S. M. Buckley1,2*, D. Abts1, R. A. Oostendorp3, D. Dzierzak3, C. M. Verfaillie1,2 1 Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA; 2Stamcel Instituut, Katholieke Universiteit Leuven, Leuven, Belgium; 3Dept. of Cell Biology and Genetics, Erasmus University, Rotterdam, the Netherlands (T45) 152 NKG2D-MEDIATED INDUCTION OF NK ACTIVITY BY ALLOGENEIC CD34+ BLOOD CELLS M. Arpinati1*, G. Chirumbolo1, M. Baccarani1, D. Rondelli1,2 1 Institute of Hematology 'Seragnoli', University of Bologna, Italy; 2 Hematology/Oncology Section, University of Illinois at Chicago, Chicago, IL, USA (T46) 95 REGULATION OF RHOA ACTIVITY BY P190-B RHOGAP IS CRITICAL FOR HEMATOPOIETIC STEM/PROGENITOR CELL HOMING AND MIGRATION H. Xu1,2*, K. Szczur1, Y. Zheng1, J. Settleman3, D. A. Williams1, M. D. Filippi1 1 Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; 2Cell and Molecular Biology Graduate Program, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 3Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA (T47) 153 CONTROLLED DELIVERY OF TAT-HOXB4 TO A CORD BLOOD HEMATOPOIETIC STEM CELL EXPANSION BIOPROCESS G. Gavigan*, H. Kowsari, T. Yin, M. Ungrin, D. Kirouac, P. W. Zandstra Institute of Biomaterials and Biomedical Engineering, University of Toronto, Donnelly CCBR Building, Toronto, Ontario, Canada (T48) 94 USE OF NOD/SCID XENOGRAPH MODEL FOR BIOLOGICAL AND MOLECULAR CHARACTERISATION OF CHILDHOOD T-ALL STEM CELLS C. V. Cox1,2*, H. M. Martin2, P. R. Kearns2,3, A. Blair1,2 1 Bristol Institute forTransfusion Sciences, Bristol, UK; 2University of Bristol, Bristol, UK; 3Clinical Sciences South Bristol, Bristol, UK

(T49) 154 IDENTIFICATION OF A RARE POPULATION OF QUIESCENT BONE MARROW-HOMED DONOR CELLS EARLY AFTER TRANSPLANTATION THAT IS ENRICHED FOR PRIMITIVE HEMATOPOIETIC POTENTIAL H. L. Chua*, N. T. Nguyen, E. F. Srour, C. M. Orschell Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA (T50) 92 CCL18/PARC STIMULATES HEMATOPOIESIS IN LONGTERM BONE-MARROW CULTURES INDIRECTLY THROUGH ITS EFFECT ON MONOCYTES I. Schraufstatter*, R. DiScipio, N. Serobyan, M. Zhao, S. Khaldoyanidi Departments of Cancer Biology and Vascular Biology, La Jolla Institute for Molecular Medicine, San Diego, CA 92121, USA (T51) 155 NATURALLY OCCURING CD4+CD25+ REGULATORY TCELLS MODULATE THE HEMATOPOIETIC POTENTIAL OF HUMAN STEM CELLS IN VITRO C. Salvador1*, M. Steurer1, A. M. Wolf1, D. Fong1, G. Gastl1, G. Konwalinka2, D. Wolf1 1 Dept. of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria; 2Dept. of General Internal Medicine, Innsbruck Medical University, Innsbruck, Austria (T52) 93 FAS AND FAS-LIGAND ARE UP-REGULATED IN TRANSPLANTED BONE MARROW CELLS WITHOUT MEDIATING APOPTOSIS M. Pearl-Yafe1*, E. S. Yolcu2, J. Stein1, I. Yaniv1, H. Shirwan2, N. Askenasy1 1 Frankel Laboratory, Department of Pediatric HematologyOncology, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel; 2Department of Immunology, University of Louisville, Louisville, KY, USA (T53) 156 NOVEL METHOD FOR EFFICIENT PRODUCTION OF MULTIPOTENTIAL HEMATOPOIETIC PROGENITORS FROM HUMAN EMBRYONIC STEM CELLS F. Ma1,3*, D. Wang1, S. Hanada1, Y. Ebihara1, H. Kawasaki1, Y. Zaike2, T. Heike3, T. Kitamura1, T. Nakahata3, K. Tsuji1 1 Division of Cellular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan; 2Department of Laboratory Medicine, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan; 3 Department of Pediatrics, Graduate School of Medicine, Kyoto University, Japan (T54) 157 INVESTIGATING THE GENES INVOLVED IN STROMA CELL MEDIATED MAINTENANCE OF HEMATOPOIETIC STEM CELLS J. Renström1*, M. Judex1, J. Mages2, R. Lang2, C. Peschel1, R. A. J. Oostendorp1 1 III. Medizinische Klinik und Poliklinik Klinikum rechts der Isar, Technical University Munich, Munich, Germany; 2Department of Microbiology and Immunology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany (T55) 98 PROTEIN PHOSPHATASE 2A PLAYS AN ESSENTIAL ROLE IN CHEMOTAXIS OF CD34+ CELLS TOWARDS SDF-1/ CXCL12 S. Basu1,2*, N. Ray3, S. J. Atkinson3, H. E. Broxmeyer1,2 1 Department of Microbiology and Immunology, Indiana University School of Medicine, IUPUI, Indianapolis, IN, USA; 2Walther Oncology Center, IUPUI, Indianapolis, IN, USA; 3Department of Medicine (Nephrology), Indiana University School, IUPUI, Indianapolis, IN, USA

iseh06.book Page 17 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34 (T56) 91 ALTERATION OF ENDOGLIN EXPRESSION DOES NOT INFLUENCE HEMATOPOIETIC STEM CELL FUNCTION, BUT MODULATES PROGENITOR SENSITIVITY TO TGF-β AND NEGATIVELY IMPACTS ERYTHROID DEVELOPMENT J. L. Moody1*, S. Singbrant1, G. Karlsson1, U. Blank1, M. Aspling1, J. Flygare1, J. Larsson1, D. Bryder2, S. Karlsson1 1 Molecular Medicine and Gene Therapy, Institute of Institute of Laboratory Medicine and The Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University Hospital, Lund, Sweden; 2Immunology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden

(T58) 52 RAC1 IS REQUIRED FOR HEMATOPOIETIC STEM/ PROGENITOR CELL SEEDING OF FETAL LIVER G. Ghiaur1,3*, M. J. Ferkovicz2, J. R. Bailey1, J. A. Cancelas1,4, M. C. Yoder2, D. A. Williams1,3 1Experimental Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; 2Indiana University School of Medicine, Indianapolis, MN, USA; 3Molecular and Developmental Biology Graduate Program, University of Cincinnati, Cincinnati, OH, USA; 4Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH, USA (T59) 53 EXPERIMENTAL EVIDENCE THAT POOR MOBILIZATION IN IMMUNODEFICIENT SCID PATIENTS COULD BE EXPLAINED BY THE LACK OF COMPLEMENT ACTIVATION AND COMPLEMENT-DEPENDENT TRIGGERING OF HSPC RELEASE FROM THE BONE MARROW R. G. Reca1*, M. Wysoczynski1, M. Kucia1, A. JanowskaWieczorek2, J. Ratajczak1, M. Z. Ratajczak1 1 Stem Cell Biology Progam at the James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA; 2Department of Medicine, University of Alberta and CBS Edmonton, AB Canada

(T62) 46 HEDGEHOG/MEIS1 COLLABORATION GENERATES A MIXED-LINEAGE B-LYMPHOID/MYELOID MURINE LEUKEMIA K. Detmer1*, B. Argiropoulos2, A. N. Walker3, A. J. Lowrey1, R. K. Humphries2 1Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, GA, USA; 2Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada; 3Department of Pathology, Mercer University School of Medicine, Macon, GA, USA (T63) 27 A CRITICAL ROLE FOR SMAD4 IN THE SELF-RENEWAL OF HEMATOPOIETIC STEM CELLS G. Karlsson1*, U. Blank1, J. L. Moody1, M. Ehinger2, S. Singbrant1, C. X. Deng3, S. Karlsson1 1Molecular Medicine and Gene Therapy and Lund Stem Cell Center, Lund University Hospital, Sweden; 2Department of Pathology, Helsingborgs Lasarett, Sweden; 3National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA (T64) 28 OPPOSING CRITICAL ROLES OF THROMBOPOIETIN AND LNK IN REGULATING HEMATOPOIETIC STEM CELL EXPANSION J. Antonchuk*, N. Buza-Vidas, J. M. Nygren, R. Månsson, C. T. Jensen, H. Qian, S. E. W. Jacobsen Stem Cell Center, University of Lund, Lund, Sweden (T65) 50 SPATIO-TEMPORAL EMERGENCE OF MULTIPOTENT HEMATOPOIETIC PRECURSORS IN THE ZEBRAFISH EMBRYO J. Y. Bertrand*, A. D. Kim, D. Traver Department of Cell and Developmental Biology, University of California San Diego, San Diego, CA, USA (T66) 26 COMPLEMENTARY AND INDEPENDENT FUNCTION FOR HOXB4 AND BMI1 IN HSC SELF-RENEWAL A. Faubert1,2*, G. Sauvageau1,2,3 1 Laboratory of Molecular Genetics of Hematopoietic Stem Cells, Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, Quebec, Canada; 2Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada; 3Department of Medicine and Division of Haematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

(T60) 29 A LIMITED ROLE FOR P21 IN MAINTAINING NORMAL HEMATOPOIETIC STEM CELL FUNCTIONING R. van Os*, L. M. Kamminga, A. Ausema, L. Bystrykh, D. Draijer, B. Dontje, G. de Haan Department of Cell Biology, section Stem Cell Biology, University Medical Center Groningen, Groningen, The Netherlands

(T67) 196 THE NUTRACEUTICAL OMEGA 6 IS A USEFUL SUPPLEMENT IN THE SERUM FREE EXPANSION MEDIUM FOR IN VITRO GENERATION OF MEGAKARYOCYTES FROM UMBILICAL CORD BLOOD CD34+ CELLS N. F. A. Siddiqui, V. P. Kale, L. S. Limaye* National Centre For Cell Science, Pune, Maharashtra, India

(T61) 51 CIRCULATION PLAYS AN ESSENTIAL ROLE IN DISTRIBUTING HEMATOPOIETIC PROGENITORS FROM THE YOLK SAC TO THE EMBRYO PROPER; LESSONS FROM THE NCX1-NULL MOUSE C. Lux1*, M. Yoshimoto1, K. McGrath2, S. Conway1, J. Palis2, M. C. Yoder1 1Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA; 2Department of Pediatrics, Center for Pediatric Biomedical Research, University of Rochester School of Medicine, Rochester, NY, USA

Immune Reconstitution (T68) 39 DIFFERENTIAL GENE EXPRESSION AND PROTEIN PRODUCTION DURING MATURATION PROCESS OF CORD BLOOD (CB) VERSUS ADULT PERIPHERAL BLOOD (APB) MONOCYTE (MO) INTO MATURE DENDRITIC CELLS (DC): INSIGHT INTO IMMATURITY OF CB CELLULAR IMMUNITY H. Jiang1*, C. Wade-Harris1, M. Lim5, L. Baxi2, M. S. Cairo1,3,4 1Departments of Pediatrics; 2Obstetrics & Gynecology; 3Pathology; 4and Medicine, NewYork-Presbyterian, Columbia University, New York, NY, USA; 5Department of Pathology, University of Utah, Salt Lake City, UT, USA

Thursday

(T57) 30 SMAD5 IS DISPENSABLE FOR ADULT MURINE HEMATOPOIESIS S. Singbrant1*, J. L. Moody1, U. Blank1, G. Karlsson1, L. Umans2, A. Zwijsen2, S. Karlsson1 1Department of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University Hospital, Lund, Sweden; 2Department of Developmental Biology, Flanders Interuniversity Institute for Biotechnology (VIB) and Laboratory of Molecular Biology (Celegen), University of Leuven, Leuven, Belgium

17

iseh06.book Page 18 Thursday, August 17, 2006 4:11 PM

18

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

Immunotherapy (T69) 158 RITUXIMAB IN THE TREATMENT OF ACQUIRED FACTOR VIII INHIBITORS A. A. Onitilo1*, A. Skorupa2, A. Lal5, E. Ronish3, R. Mercier1, R. Islam1, J. Lazarchick4 1 Department of Hematology/Oncology, Marshfield Clinic Weston Center, Weston, WI, USA; 2Hematology/Oncology Division,, Medical University of South Carolina, Charleston, SC, USA; 3 Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA; 4Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA; 5Lexington Medical Center, West Columbia, SC, USA; 6Department of Hematology/Oncology, Marshfield Clinic, Marshfield, WI, USA (T70) 159 ACCELERATING THE CATABOLISM OF AUTOIMMUNE IGG H. M. Vriesendorp Self employed (T71) 23 SIGNIFICANT DIFFERENCES IN NATURAL KILLER (NK) CELL SUBSETS AND NATURAL KILLER RECEPTOR (NKR) EXPRESSION IN PERIPHERAL BLOOD (PB) VERSUS CORD BLOOD (CB): IMPLICATIONS IN IMMATURITY OF CB (NEONATAL) INNATE IMMUNITY E. Shereck1*, P. Satwani1, C. van de Ven1, R. J. Wapner2, N. Day1, H. Jiang1, M. S. Cairo1,3,4 1 Departments of Pediatrics; 2Obstetrics/Gynecology; 3Pathology; 4 and Medicine, Morgan Stanley Children's Hospital of NewYorkPresbyterian, Columbia University, New York, NY, USA (T72) 24 A SUBPOPULATION OF HUMAN NK CELLS LACKING INHIBITORY RECEPTORS FOR SELF MHC IS DEVELOPMENTALLY IMMATURE RATHER THAN AUTOREACTIVE S. Cooley1*, F. Xiao1, M. Pitt1, M. Gleason1, V. McCullar1, T. Bergemann2, K. McQueen3, L. Guethlein3, P. Parham3, J. S. Miller1 1 Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, USA; 2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA; 3Department of Structural Biology, Sherman Fairchild Building, 299 Campus Drive West, Stanford University School of Medicine, Stanford, CA, USA (T73) 74 CD20-TARGETED T CELLS FOR IMMUNE CONSOLIDATION AFTER PBSCT FOR NONHODGKINS LYMPHOMA (NHL) TO IMPROVE GRAFT-VS-LYMPHOMA EFFECTS (GVL) L. G. Lum1,2,3,5*, P. A. Davol1, E. L. Palushock1, L. P. Cousens1,2,3, A. L. Olson1, E. Winer3, R. Rathore1,2, G. A. Colvin2,3,4, M. Abedi2,3,4, P. J. Quesenberry2,3,4 1 Department of Immunotherapy, Roger Williams Hospital, Providence, RI, USA; 2Department of Medicine, Boston University, Boston, MA, USA; 3Adele R. Decof Cancer Center, Roger Willaims Hospital, Providence, RI, USA; 4Department of Research, Roger Williams Hospital, Providence, RI, USA; 5Department of Medicine, Brown University, Providence, RI, USA (T74) 73 ELIMINATION OF HUMAN ACUTE MYELOID LEUKEMIA (AML) CELLS USING AN ANTI-CD33 MAYTANSINOID IMMUNOCONJUGATE N. C. Hebib1, F. Larochelle1*, B. Lutz2, J. Lambert2, J. Hébert1, W. Blattler2, D. C. Roy1 1 Hematology-Oncology, Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada; 2ImmunoGen Inc., Cambridge, MA, USA

(T75) 75 SPECIFIC ANTITUMOR EFFECT OF A DENDRITIC CELLBASED VACCINE LOADED WITH PHOTODYNAMICALLY TREATED TUMOR CELLS Q. Y. Dai1*, M. Guerin1, C. Maldonado1, C. Scotto2, D. C. Roy1 1Hopital Maisonneuve-Rosemont Research Centre, Montreal, Canada; 2Celmed BioSciences, Montreal, Canada

Marrow Failure (T76) 160 A PURE HEMATOLOGICAL SYNDROME SECONDARY TO AN ACCIDENTAL RADIATION EXPOSURE TREATED WITH G-CSF, EPO, AND SCF T. Fagot1, J. F. Bottollier2, L. Roy2, T. Samson1, F. Desangles3, J. J. Lataillade4, J. M. Bertho2, C. Cailliot5, P. Gourmelon2, T. de Revel1* 1Service d'Hématologie, Hôpital d'Instruction des Armées Percy, Clamart, France; 2Direction de la Radioprotection de l'Homme, IRSN, Fontenay aux Roses, France; 3Laboratoire de Cytogénétique, Hôpital du Val-de-Grâce, Paris, France; 4Centre de Transfusion des Armées, Clamart, France; 5Amgen France, INC., Neuilly-sur-Seine, France (T77) 161 STROMAL INJURY IN MOUSE MODELS OF INFUSIONINDUCED BONE MARROW FAILURE AND THE ROLE OF REGULATORY T CELLS E. A. Erie*, F. M. Ellison, N. S. Young, J. Chen Hematology Branch, National Heart Lung and Blood Institute, National Institute of Health, Bethesda, MD, USA (T78) 40 LYMPHOCYTES EXPANSION, V-BETA SHIFTING, AND REGULATORY T CELL SUPPRESSION IN IMMUNEMEDIATED BONE MARROW FAILURE J. Chen*, N. S. Young Hematology Branch, National Heart Lung and Blood Institute, National Institute of Health, Bethesda, MD, USA

Stem Cell Biology 1 (T79) 187 INCREASED MOBILIZATION PROFICIENCY IN AGED MICE M. A. Ryan1, Z. Xing1, D. Daria1, K. J. Nattamai1, G. Van Zant2, L. Wang1, Y. Zheng1, H. Geiger1* 1Division of Experimental Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati OH, USA; 2Departments of Internal Medicine and Physiology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA (T80) 101 CULTIVATION OF HUMAN EMBRYONIC STEM CELLDERIVED EMBRYOID BODIES UNDER DEFINED ENVIRONMENTAL CONDITIONS C. M. Cameron1*, F. Harding1,2, W-S. Hu1, D. S. Kaufman2 1Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN, USA; 2Stem Cell Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

iseh06.book Page 19 Thursday, August 17, 2006 4:11 PM

35th Annual Scientific Meeting: ISEH / Experimental Hematology 34 (2006) 1-34

18:15–20:15

19

Lake Calhoun

EMERGING LEADERS TASK FORCE SESSION Developing a Scientific Career in a Changing Landscape - A Panel Discussion by Industry and Academia Moderator: Craig Eckfeldt (University of Minnesota)

Dr. Allen Eaves (British Columbia Cancer Agency) Dr. Glenn Begley (Amgen Inc.) Dr. Sophia Khaldoyanidi (La Jolla Institute for Molecular Medicine) Dr. Stefan Karlsson (Lund University) Dr. Susie Nilsson (Australian Stem Cell Centre) Erin Drew (University of British Columbia) 18:15–19:15 Each invited speaker will give a ten-minute PowerPoint slide presentation. During this informal presentation, the speakers will introduce themselves and explain their perspectives to the audience. The speakers will describe the academic institution/company that they represent and will discuss how their career path developed. Based on this, advice will be given to young and emerging leaders in hematology/stem cell biology with particular emphasis on how to develop a successful career in an ever-changing environment. 19:15–20:15 - Question and Answer portion *Q/A is not only designated for the above stated time - this session is informal and we encourage audience participation throughout the session.

20:15

Greenway AJ

EMERGING LEADERS TASK FORCE RECEPTION

Thursday

The ELTF session will address the different perspectives in the field of hematology. This is an open forum for Industry and Academia to discuss the many career opportunities within the field.